semaglutide patient education pdf How 'miracle' weight‐loss promises to change medicine but can we afford the expense? - Weiskirchen - 2025 - British Journal of Pharmacology Spotlight on the Mechanism of

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for glycaemic control in adults with type 2 diabetes mellitus

Large manufacturers are anchoring this shift with multibillion-dollar site investments tied to tirzepatide and the oral pipeline, while CDMOs are consolidating peptide capabilities, including CordenPharma's 2026 acquisition of AmbioPharm to expand U.S.-based peptide API options

Beyond its core therapeutic area, Novo Nordisk is gradually building a stronger business elsewhere, especially in rare blood diseases

10.1007/s00125-009-1637-8 69 TianJ.WenH.ZengL.JiangM.WuF.LiuW.et al (2013)

Novo Nordisk submitted its application to the FDA to expand the indication for Rybelsus to reduce the risk of MACE in patients with type 2 diabetes and established CVD and/or chronic kidney disease